Medicine and Dentistry
Biological Marker
100%
Malignant Neoplasm
100%
Meta-Analysis
100%
Immune Checkpoint Inhibitor
100%
Hazard Ratio
100%
Programmed Death 1 Ligand 1
100%
Overall Survival
58%
Neoplasm
25%
Lung Cancer
16%
Subgroup Analysis
16%
Diseases
8%
Nodular Melanoma
8%
Cancer Localization
8%
Head and Neck Cancer
8%
Adverse Event
8%
Recurrent Disease
8%
Avelumab
8%
Cancer Types
8%
DNA Mismatch Repair
8%
Progression Free Survival
8%
Gastroesophageal Junction
8%
Nivolumab
8%
Side Effect
8%
Conception
8%
English (Language)
8%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
100%
Malignant Neoplasm
100%
Biological Marker
100%
Programmed Death 1 Ligand 1
100%
Overall Survival
77%
Chemotherapy
33%
Neoplasm
33%
Lung Cancer
22%
Disease
11%
Head and Neck Cancer
11%
Adverse Event
11%
Melanoma
11%
Recurrent Disease
11%
Side Effect
11%
Progression Free Survival
11%
Nivolumab
11%
Avelumab
11%
Biochemistry, Genetics and Molecular Biology
Immune Checkpoints
100%
Overall Survival
100%
English (Language)
14%
Conception
14%
Embase
14%
Medline
14%
Progression Free Survival
14%
DNA Mismatch Repair
14%
Cochrane Library
14%
Web of Science
14%
Immunology and Microbiology
Programmed Death 1 Ligand 1
100%
Overall Survival
77%
Mismatch Repair
11%
Neck
11%
Conception
11%
Embase
11%
Cochrane Library
11%
Medline
11%
Progression Free Survival
11%
Web of Science
11%
Nivolumab
11%
Gastroesophageal Junction
11%
Avelumab
11%